TNF and psoriasis: Moreover, the clinical efficacy by using adalimumab (anti-TNF-α) therapy in psoriatic patients is mainly through inhibiting p38 activity to further reduce expression of certain p38 kinase-regulated pro-inflammatory cytokines, indicating that targeting p38 could be a promising strategy to treat psoriasis (12).